Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients: 
Five Cases and Review of Literature

Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients: 
Five Cases and Review of Literature

Background and objective Vandetanib is a once-daily oral multi-target inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases. The current study aimed to evaluate the effect and safety of vandetanib adminis...

Descrición completa

Detalles Bibliográficos
Main Authors: Lili GUO, Junfang TANG, Qiyi MENG, Yunzhong ZHU, Liyan XU, Heling SHI, Zhe LIU
Formato: Artigo
Idioma:zho
Publicado: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-02-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Vandetanib
EGFR-TKIs
Acceso en liña:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.11

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.11

Títulos similares